We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. (ABBV - Free Report) , PepsiCo, Inc. (PEP - Free Report) , Oracle Corp. (ORCL - Free Report) , HSBC Holdings plc (HSBC - Free Report) and The Progressive Corp. (PGR - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for AbbVie, PepsiCo and Oracle
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., PepsiCo, Inc. and Oracle Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
AbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+21.4% vs. +13.0%) reflecting the company's robust drug pipeline. The company has successfully expanded labels of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023.
Skyrizi and Rinvoq have established outstanding launch trajectories bolstered by the approval of new indications. It has several early/mid-stage candidates that have blockbuster potential. Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas, enhancing its long-term growth potential.
However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica's sales. Slowing consumer demand due to economic pressures is affecting aesthetics franchise sales.
Shares of PepsiCo have gained +6.9% over the past year, modestly lagging Coke's +9.5% gain, but handily outperforming the broader market's -21.2% decline. The company's revenues and earnings beat the Zacks Consensus Estimate and improved year over year in the third quarter. This marked the 17th straight quarter of sales beat.
PepsiCo benefits from the resilience and strength of global beverage and convenient food businesses. It expects to benefit by delivering convenience, variety and value proposition to customers through its brands. It raised its revenue view for 2022.
However, PepsiCo witnessed margin pressures in the third quarter driven by impacts of supply-chain disruptions and inflationary labor, transportation and commodity costs. PEP anticipates incremental input cost inflation for the balance of 2022. Adverse currency rates also remain headwinds.
Shares of Oracle have declined -8.8% over the past year against the Zacks Computer - Software industry's decline of -31.0%. The company is spending high on product enhancements, especially toward the cloud platform, and is likely to limit margin expansion. The Zacks analyst expects fiscal 2023 non-GAAP operating expenses to jump 18.3% over fiscal 2022.
Nevertheless, Oracle's second-quarter fiscal 2023 results benefitted from strength in infrastructure and applications cloud businesses. Solid adoption of cloud-based applications, comprising NetSuite Enterprise Resource Planning (ERP), Fusion ERP and Fusion Human Capital Management (HCM), bodes well.
Solid demand for the Oracle Dedicated Region Cloud@Customer is anticipated to drive the top line. Oracle expects total cloud growth, including Cerner, to grow from 43% to 47% in USD for the next quarter. Partnerships with Accenture and Microsoft are helping Oracle win new clientele.
Other noteworthy reports we are featuring today include HSBC Holdings plc and The Progressive Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive
For Immediate Release
Chicago, IL – December 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. (ABBV - Free Report) , PepsiCo, Inc. (PEP - Free Report) , Oracle Corp. (ORCL - Free Report) , HSBC Holdings plc (HSBC - Free Report) and The Progressive Corp. (PGR - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for AbbVie, PepsiCo and Oracle
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., PepsiCo, Inc. and Oracle Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
AbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+21.4% vs. +13.0%) reflecting the company's robust drug pipeline. The company has successfully expanded labels of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023.
Skyrizi and Rinvoq have established outstanding launch trajectories bolstered by the approval of new indications. It has several early/mid-stage candidates that have blockbuster potential. Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas, enhancing its long-term growth potential.
However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica's sales. Slowing consumer demand due to economic pressures is affecting aesthetics franchise sales.
(You can read the full research report on AbbVie here >>>)
Shares of PepsiCo have gained +6.9% over the past year, modestly lagging Coke's +9.5% gain, but handily outperforming the broader market's -21.2% decline. The company's revenues and earnings beat the Zacks Consensus Estimate and improved year over year in the third quarter. This marked the 17th straight quarter of sales beat.
PepsiCo benefits from the resilience and strength of global beverage and convenient food businesses. It expects to benefit by delivering convenience, variety and value proposition to customers through its brands. It raised its revenue view for 2022.
However, PepsiCo witnessed margin pressures in the third quarter driven by impacts of supply-chain disruptions and inflationary labor, transportation and commodity costs. PEP anticipates incremental input cost inflation for the balance of 2022. Adverse currency rates also remain headwinds.
(You can read the full research report on PepsiCo here >>>)
Shares of Oracle have declined -8.8% over the past year against the Zacks Computer - Software industry's decline of -31.0%. The company is spending high on product enhancements, especially toward the cloud platform, and is likely to limit margin expansion. The Zacks analyst expects fiscal 2023 non-GAAP operating expenses to jump 18.3% over fiscal 2022.
Nevertheless, Oracle's second-quarter fiscal 2023 results benefitted from strength in infrastructure and applications cloud businesses. Solid adoption of cloud-based applications, comprising NetSuite Enterprise Resource Planning (ERP), Fusion ERP and Fusion Human Capital Management (HCM), bodes well.
Solid demand for the Oracle Dedicated Region Cloud@Customer is anticipated to drive the top line. Oracle expects total cloud growth, including Cerner, to grow from 43% to 47% in USD for the next quarter. Partnerships with Accenture and Microsoft are helping Oracle win new clientele.
(You can read the full research report on Oracle here >>>)
Other noteworthy reports we are featuring today include HSBC Holdings plc and The Progressive Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.